Volume 21, Number 8—August 2015
Dispatch
Geographic Distribution and Expansion of Human Lyme Disease, United States
Table
Location, period | No. counties | Relative risk, range† | Average annual incidence, range‡ | No. counties added to high-incidence status | No. counties removed from high- incidence status |
---|---|---|---|---|---|
Overall | |||||
1993–1997 | 69 | 2.3–91.1 | 10.6–402.7 | NA | NA |
1998–2002 | 130 | 2.0–152.6 | 12.3–912.9 | 71 | 10 |
2003–2007 | 197 | 2.0–101.3 | 15.0–742.8 | 72 | 5 |
2008–2012 |
260 |
2.0–48.6 |
15.9–381.4 |
72 |
9 |
Northeastern focus | |||||
1993–1997 | 43 | 2.3–91.1 | 10.6–402.7 | NA | NA |
1998–2002 | 90 | 2.0–152.6 | 12.3–912.9 | 50 | 3 |
2003–2007 | 130 | 2.0–101.3 | 15.0–742.8 | 45 | 5 |
2008–2012 |
182 |
2.0–48.6 |
15.9–381.4 |
60 |
8 |
North-central focus | |||||
1993–1997 | 22 | 2.6–41.3 | 12.1–189.6 | NA | NA |
1998–2002 | 40 | 2.0–35.3 | 12.4–217.3 | 21 | 3 |
2003–2007 | 67 | 2.0–29.8 | 15.0–222.7 | 27 | 0 |
2008–2012 | 78 | 2.1–28.1 | 16.1–220.7 | 12 | 1 |
*In the first period, 4 counties in the southeastern United States met high-incidence criteria but are not included in the geographic focus–specific data. NA, not applicable.
†Relative risk is observed number of cases over a period divided by expected number of cases for the population at risk (4). For this analysis, high-incidence counties had a relative risk of >2.0.
‡Incidence is reported cases per 100,000 residents per year; population used was average population at risk during a period (US census data for midpoint of each period).
References
- Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. Lancet. 2012;379:461–73. DOIPubMedGoogle Scholar
- Steere AC, Coburn J, Glickstein L. The emergence of Lyme disease. J Clin Invest. 2004;113:1093–101. DOIPubMedGoogle Scholar
- Adams DA, Jajosky RA, Ajani U, Kriseman J, Sharp P, Onwen DH, et al. Summary of notifiable diseases—United States, 2012. MMWR Morb Mortal Wkly Rep. 2014;61:1–121.PubMedGoogle Scholar
- National Notifiable Diseases Surveillance System (NNDSS). Lyme disease (Borrelia burgdorferi). Case definitions [cited 2014 Oct 20]. http://wwwn.cdc.gov/nndss/script/conditionsummary.aspx?CondID=100
- Kulldorff M. SaTScan: software for the spatial, temporal, and space-time scan statistics. 2011 [cited 2013 Mar15]. http://www.satscan.org
- Connally NP, Ginsberg HS, Mather TN. Assessing peridomestic entomological factors as predictors for Lyme disease. J Vector Ecol. 2006;31:364–70. DOIPubMedGoogle Scholar
- Pepin KM, Eisen RJ, Mead PS, Piesman J, Fish D, Hoen AG, Geographic variation in the relationship between human Lyme disease incidence and density of infected host-seeking Ixodes scapularis nymphs in the eastern United States. Am J Trop Med Hyg. 2012;86:1062–71. DOIPubMedGoogle Scholar
- Chen H, White DJ, Caraco TB, Stratton HH. Epidemic and spatial dynamics of Lyme disease in New York State, 1990–2000. J Med Entomol. 2005;42:899–908.PubMedGoogle Scholar
- Frank C, Fix AD, Pena CA, Strickland GT. Mapping Lyme disease incidence for diagnostic and preventive decisions, Maryland. Emerg Infect Dis. 2002;8:427–9. DOIPubMedGoogle Scholar
- Bacon RM, Kugeler KJ, Mead PS. Surveillance for Lyme disease—United States, 1992–2006. MMWR Surveill Summ. 2008;57:1–9.PubMedGoogle Scholar
- Waller LA, Goodwin BJ, Wilson ML, Ostfeld RS, Marshall SL, Hayes EB. Spatio-temporal patterns in county-level incidence and reporting of Lyme disease in the northeastern United States, 1990–2000. Environ Ecol Stat. 2007;14:83–100. DOIGoogle Scholar
- Kitron U, Kazmierczak J. Spatial analysis of the distribution of Lyme disease in Wisconsin. Am J Epidemiol. 1997;145:558–66. DOIPubMedGoogle Scholar
- Eisen RJ, Lane RS, Fritz CL, Eisen L. Spatial patterns of Lyme disease risk in California based on disease incidence data and modeling of vector-tick exposure. Am J Trop Med Hyg. 2006;75:669–76.PubMedGoogle Scholar
- Teutsch SM, Churchill RE, editors. Principles and practices of public health surveillance. 2nd ed. New York: Oxford; 2000.
- Wormser GP, Masters E, Nowakowski J, McKenna D, Holmgren D, Ma K, Prospective clinical evaluation of patients from Missouri and New York with erythema migrans-like skin lesions. Clin Infect Dis. 2005;41:958–65. DOIPubMedGoogle Scholar
Page created: May 11, 2016
Page updated: May 11, 2016
Page reviewed: May 11, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.